Interestingly, the indicated difference in CCL2 protein levels was also apparent in CCR2 KO mice, showing that it is not the mere extent of tumor burden that determines CCL2 amounts but, instead, the ability of tumor cells to produce CCL2, a capacity that is impaired in the absence of TRAIL-R (Figure 6C). The gene discussed is CCR2; the disease is neoplasm.